TY  - JOUR
AU  - Machiels, J-P
AU  - Tao, Y
AU  - Burtness, B
AU  - Tahara, M
AU  - Licitra, L
AU  - Rischin, D
AU  - Waldron, J
AU  - Simon, C
AU  - Gregoire, V
AU  - Harrington, K
AU  - Alves, GV
AU  - Lima, IPF
AU  - Pointreau, Y
AU  - Hughes, BGM
AU  - Aksoy, S
AU  - Hetnal, M
AU  - Ge, JY
AU  - Brown, H
AU  - Cheng, J
AU  - Bidadi, B
AU  - Siu, LL
Y2  - 2020/11/27
Y1  - 2020/06/03
SN  - 1479-6694
UR  - http://hdl.handle.net/11343/252429
AB  - Current treatment guidelines for patients with locally advanced head and neck squamous cell carcinoma (HNSCC) recommend multimodal treatment, including chemoradiation therapy (CRT) or surgery followed by radiation, with or without chemotherapy. The immune checkpoint inhibitor pembrolizumab has previously demonstrated antitumor activity in recurrent and/or metastatic HNSCC in large Phase III trials. For patients with locally advanced disease, Phase Ib data on the use of pembrolizumab in combination with chemoradiation have shown the approach to be safe and feasible. We describe here the design and rationale for KEYNOTE-412, a randomized, double-blind, Phase III trial investigating pembrolizumab or placebo administered concurrently with CRT and as maintenance treatment in patients with locally advanced HNSCC.
LA  - English
PB  - FUTURE MEDICINE LTD
T1  - Pembrolizumab given concomitantly with chemoradiation and as maintenance therapy for locally advanced head and neck squamous cell carcinoma: KEYNOTE-412
DO  - 10.2217/fon-2020-0184
IS  - Future Oncology
VL  - 16
IS  - 18
SP  - 1235-1243
L1  - /bitstream/handle/11343/252429/fon-2020-0184.pdf?sequence=1&isAllowed=y
ER  -